Earnings summaries and quarterly performance for Hyperfine.
Executive leadership at Hyperfine.
Board of directors at Hyperfine.
Research analysts who have asked questions during Hyperfine earnings calls.
Brandon Carney
B. Riley
3 questions for HYPR
Also covers: CATX, RDNT, VREX
Frank Takkinen
Lake Street Capital Markets
2 questions for HYPR
Also covers: ANGO, AORT, AXGN +17 more
XL
Xuyang Li
Jefferies
2 questions for HYPR
Also covers: BLCO, SIBN
YZ
Yuan Zhi
B. Riley Financial, Inc.
2 questions for HYPR
Also covers: LNTH, MIR, OCX +4 more
LB
Larry Biegelsen
Wells Fargo & Company
1 question for HYPR
Also covers: ABT, ALC, AXNX +24 more
SK
Simran Kaur
Wells Fargo & Company
1 question for HYPR
Also covers: PODD, RXST
Recent press releases and 8-K filings for HYPR.
Hyperfine Announces Breakthrough Clinical Data for Swoop® System Stroke Detection
HYPR
Product Launch
New Projects/Investments
- Hyperfine, Inc. announced the publication of breakthrough clinical data demonstrating the Swoop® system's enhanced stroke detection capabilities.
- The study, which evaluated 95 patients, showed that the next-generation Swoop® system with an advanced multi-directional DWI sequence achieved 100% sensitivity and 100% specificity for lesions greater than 1.0 mL.
- The next-generation Swoop® system also successfully identified lesions as small as 2.8 mm (0.15 mL) and reduced scan time by approximately 30%.
- Maria Sainz, President and CEO of Hyperfine, commented that stroke detection is a critical driver of the Swoop® system's expansion into emergency departments.
Jan 27, 2026, 1:15 PM
Hyperfine Announces NEURO PMR Study Results
HYPR
Product Launch
New Projects/Investments
- Hyperfine announced positive results from its NEURO PMR study, which evaluated the clinical utility and patient experience of its portable Swoop® MRI system compared to standard-of-care MRI in outpatient neurology clinics.
- The study found that portable MRI demonstrated 92% concordance with standard MRI in identifying intracranial pathology during a blinded review, which increased to 98% in unblinded paired image reviews.
- Patients expressed a strong preference for portable MRI, being four times more likely to choose it over standard MRI due to superior ratings across comfort, anxiety, claustrophobia, noise, and overall satisfaction.
- The Swoop® system is designed to be portable, fit in an exam room, and requires no specialized infrastructure, allowing existing clinic staff to perform scans, and is eligible for reimbursement under existing brain MRI CPT codes after site accreditation.
Jan 20, 2026, 1:15 PM
Hyperfine Reports Preliminary Q4 and Full Year 2025 Financial Results
HYPR
Earnings
Revenue Acceleration/Inflection
Product Launch
- Hyperfine reported preliminary, unaudited revenue of approximately $5.3 million for Q4 2025, representing 54% sequential growth compared to Q3 2025, and $13.5 million for the full year 2025.
- The company expects preliminary, unaudited cash and cash equivalents of approximately $35.1 million as of December 31, 2025.
- Net cash burn for Q4 2025 is expected to be approximately $5.7 million, a 3% sequential decrease from Q3 2025, and $29.9 million for the full year 2025.
- The record fourth quarter was driven by success across all business verticals, including placements in hospitals, neurology offices, and international markets, following the recent launches of the next generation Swoop® System and Optive AI™ software.
Jan 12, 2026, 1:28 PM
Hyperfine Reports Preliminary Q4 and Full Year 2025 Financial Results
HYPR
Earnings
Revenue Acceleration/Inflection
Guidance Update
- Hyperfine reported preliminary, unaudited fourth quarter 2025 revenue of approximately $5.3 million, representing 127% growth compared to Q4 2024 and 54% sequential growth from Q3 2025.
- Preliminary, unaudited full year 2025 revenue is expected to be approximately $13.5 million, a 5% increase over the prior year.
- The company anticipates preliminary, unaudited net cash burn for Q4 2025 (excluding financings) to be approximately $5.7 million, a 30% decrease compared to Q4 2024, and expects to have approximately $35.1 million in cash and cash equivalents as of December 31, 2025.
- CEO Maria Sainz highlighted the record fourth quarter, attributing it to success across business verticals, mainstream adoption of their technology, and entry into the new neurology office market.
Jan 12, 2026, 1:15 PM
Hyperfine Announces Peer-Reviewed Publication on Economic Benefits of Swoop® Portable MRI System
HYPR
New Projects/Investments
Revenue Acceleration/Inflection
- Hyperfine announced the first peer-reviewed publication demonstrating the significant economic benefits of its Swoop® AI-powered portable MRI system in acute hospital care.
- A 12-month retrospective analysis conducted at Jefferson Abington Hospital found that the Swoop® system generated cost savings and workflow efficiencies.
- The analysis indicated that using the Swoop® system can avoid an average cost of $590 per patient by eliminating the need for MR-compatible equipment transitions and reduce MRI wait times by an average of eighteen hours for ICU and ED patients.
- These combined benefits of cost avoidance, increased throughput, and time savings contribute to a compelling health economic profile for hospitals, potentially leading to a shorter return on investment for the Swoop® system.
Jan 6, 2026, 1:15 PM
Hyperfine, Inc. Amends At-The-Market Equity Offering Program
HYPR
- Hyperfine, Inc. entered into an Amended and Restated At Market Issuance Sales Agreement on December 29, 2025, allowing it to offer and sell up to $50.0 million of its Class A common stock.
- The amended agreement adds BTIG, LLC as an additional sales agent, joining B. Riley Securities, Inc., with no other material terms of the program being amended.
- The company will pay the sales agents a commission of up to three percent (3.0%) of the gross sales proceeds.
- The previous at-the-market offering, under which 3,464,325 shares of Class A common stock were sold for approximately $4.35 million in aggregate gross proceeds, has been terminated.
Dec 29, 2025, 9:17 PM
Hyperfine Receives Regulatory Approval for Swoop® System in India
HYPR
Product Launch
New Projects/Investments
- Hyperfine (Nasdaq: HYPR) has secured regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) for its Swoop® system, an FDA-cleared AI-powered portable MRI system for the brain.
- This approval opens a major global market for Hyperfine, with the commercial launch in India slated for early 2026.
- The company will partner with Radiosurgery Global, Ltd. (RSG) for distribution, leveraging the Swoop® system's portability, low infrastructure requirements, and affordability to address India's significant unmet need for neuroimaging.
Dec 17, 2025, 1:15 PM
Hyperfine Receives FDA Clearance for Advanced Stroke Detection Software Update
HYPR
Product Launch
New Projects/Investments
- Hyperfine, Inc. (Nasdaq: HYPR) announced FDA clearance for its first Optive AI™ Software Update for the Swoop® system, featuring a new multi-direction diffusion-weighted imaging (DWI) sequence.
- This update is designed to enhance stroke detection by delivering clearer, higher-quality images, improving sensitivity for detecting smaller strokes and diagnostic confidence in acute neurological care.
- The company's CEO, Maria Sainz, stated this is a pivotal milestone for expanding the Swoop® system's role in stroke care and positions Hyperfine to capture significant opportunities in stroke diagnosis.
Dec 15, 2025, 1:15 PM
Hyperfine Highlights Next-Gen Swoop Scanner and Market Opportunity
HYPR
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Hyperfine (HYPR) offers the first FDA-cleared portable brain MRI, the Swoop scanner, which operates at 64 millitesla and enables MRI access in non-traditional settings like critical care units and emergency rooms, bringing the scan to the patient.
- The company recently launched its next-generation Swoop scanner with Optive AI software in Q3 2025, following FDA clearance in late May, which is expected to drive commercial expansion across hospital, office, and international verticals.
- Hyperfine estimates its current total addressable market (TAM) at approximately $6 billion, with a long-term vision to expand into community settings, potentially increasing the TAM to over $15 billion.
- In Q3, Hyperfine reported strong financial performance with revenue up 27% to $3.4 million and a sequential 27% reduction in cash burn, supported by attractive gross margins and spending discipline.
Dec 4, 2025, 1:10 PM
Hyperfine Highlights Next-Generation Portable Brain MRI and Strong Q3 Performance
HYPR
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- Hyperfine has developed the first FDA-cleared portable brain MRI, the Swoop scanner, which operates at 64 millitesla and enables MRI access in critical care units, emergency rooms, and operating theaters without requiring shielded facilities.
- The company estimates its current total addressable market at $6 billion, with a long-term vision to expand into community and primary care settings, potentially growing the market opportunity to north of $15 billion.
- Hyperfine recently de-risked its growth strategy with the FDA clearance at the end of May and Q3 launch of its next-generation Swoop scanner featuring Optive AI software, which provides enhanced image quality.
- The company reported strong Q3 performance, with revenue up 27% to $3.4 million and cash burn down 27% sequentially.
- Hyperfine's business model involves an upfront CapEx sale of the Swoop system, with an MSRP of $550,000 in the U.S., complemented by annual software and service fees of approximately 10% of the purchase price for years two through five.
Dec 4, 2025, 1:10 PM
Quarterly earnings call transcripts for Hyperfine.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more